News Related to Levodopa

Related coverage linked through entity extraction aliases.

Prothena Q4 2025 Earnings: Two Partnered Programs Enter Phase III, Cash Position Exceeds Guidance

Feb 21, 2026

Prothena reported Q4 2025 adjusted loss of 45 cents per share, meeting estimates, while ending the year with $308.4 million in cash. Roche and Novo Nordisk advanced partnered programs prasinezumab and coramitug into Phase III trials.

Serina Therapeutics Enrolls First Patient in Phase 1b Trial of SER-252 for Parkinson's Disease

Feb 19, 2026

Serina Therapeutics has enrolled the first patient in its Phase 1b registrational trial evaluating SER-252 in patients with advanced Parkinson's disease in Australia, with dosing expected to begin in the first quarter of 2026.